Vijai et al.1414 Upadhyaya VD, Bhatnagar A, Kumar B, Neyaz Z, Kishore JS, Sthapak E. Is multiple session of intralesional bleomycin mandatory for complete resolution of macrocystic lymphatic malformation? Indian J Plast Surg. 2018;51:60-5.
|
2019 |
India |
Retrospective study |
21 |
8/13 |
3m‒18Y |
19 |
Not available |
0.5 mg/kg |
Porwal et al.1515 Porwal PK, Dubey KP, Morey A, Singh H, Pooja S, Bose A. Bleomycin sclerotherapy in lymphangiomas of head and neck: prospective study of 8 cases. Indian J Otolaryngol Head Neck Surg. 2018;70:145-8.
|
2017 |
India |
Prospective study |
8 |
5/3 |
4‒54Y |
7 |
Macrocystic > 1 cm |
0.5 mg/kg |
Microcystic < 1 cm |
Sindel et al.1616 Sindel A, Sayan A, Özgür Ö, Sindel T, Ilankovan V. Percutaneous treatment of orofacial vascular malformations. Br J Oral Maxillofac Surg. 2018;56:206-11.
|
2017 |
Turkey |
Prospective study |
11 |
5/6 |
18‒51Y |
11 |
Not available |
15 mg |
Ankur et al.1717 Bhatnagar A, Upadhyaya VD, Kumar B, Neyaz Z, Kushwaha A. Aqueous intralesional bleomycin sclerotherapy in lymphatic malformation: Our experience with children and adult. Natl J Maxillofac Surg. 2017;8:130-5.
|
2017 |
India |
Retrospective study |
27 |
15/12 |
3M‒52Y |
17 |
Macrocystic > 1 cm |
0.5 mg/kg |
Microcystic < 1 cm |
Ros et al.1818 Da Ros V, Iacobucci M, Puccinelli F, Spelle L, Saliou G. Lymphographic-like technique for the treatment of microcystic lymphatic malformation components of < 3 mm. AJNR Am J Neuroradiol. 2018;39:350-4.
|
2017 |
Switzerland |
Prospective study |
16 |
5/11 |
1‒47Y |
14 |
Not available |
0.5 mk/kg |
Lee et al.1919 Lee H-J, Kim T-W, Kim J-M, Kim G-W, Ko H-C, Kim B-S, et al. Percutaneous sclerotherapy using bleomycin for the treatment of vascular malformations. Int J Dermatol. 2017;56:1186-91.
|
2017 |
Korea |
Retrospective study |
9 |
4/5 |
10‒67Y |
7 |
Not available |
1 mg/kg |
Yılmaz et al.2020 Yılmaz H, Yılmaz Ö, Çamlıdağ İ, Belet Ü, Akan H. Single center experience with intralesional bleomycin sclerotherapy for lymphatic malformations. Jpn J Radiol. 2017;35:590-6.
|
2017 |
Turkey |
Retrospective study |
10 |
6/4 |
2D‒32Y |
10 |
Macrocystic > 2 cm |
1 mg/kg |
Microcystic < 2 cm |
Raichura et al.2121 Raichura ND, Alam MS, Noronha VO, Mukherjee B. A prospective study of the role of intralesional bleomycin in orbital lymphangioma. J AAPOS. 2017;21:146-51.
|
2017 |
Mexico |
Prospective study |
13 |
5/8 |
1‒32Y |
12 |
Not available |
0.5 mg/kg |
Ardıçlı et al.2222 Ardıçlı B, Karnak İ, Çiftçi AÖ, Tanyel FC, Şenocak ME. Sclerotherapy with bleomycin versus surgical excision for extracervical cystic lymphatic malformations in children. Surg Today. 2016;46:97-101.
|
2015 |
Turkey |
Retrospective study |
13 |
Not available |
1‒17Y |
12 |
Macrocystic > 2 cm |
0.25 mg/kg |
Microcystic < 2 cm |
Olimpio et al.2323 Olímpio Hde O, Bustorff-Silva J, Oliveira Filho AG, Araujo KC. Cross-sectional study comparing different therapeutic modalities for cystic lymphangiomas in children. Clinics (Sao Paulo). 2014;69:505-8.
|
2014 |
Brazil |
Retrospective study |
4 |
1/3 |
Not available |
3 |
Macrocystic > 1 cm |
0.5 mg/kg |
Microcystic < 1 cm |
Chaudry et al.2424 Chaudry G, Guevara CJ, Rialon KL, Kerr C, Mulliken JB, Greene AK, et al. Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation. Cardiovasc Intervent Radiol. 2014;37:1476-81.
|
2014 |
America |
Retrospective study |
31 |
10/21 |
3M‒31Y |
12 |
Not available |
1‒15 mg |
Erikçi et al.2525 Erikçi V, Hoşgör M, Yıldız M, Örnek Y, Aksoy N, Okur Ö, et al. Intralesional bleomycin sclerotherapy in childhood lymphangioma. Turk J Pediatr. 2013;55:396-400.
|
2013 |
Turkey |
Retrospective study |
14 |
Not available |
0‒9Y |
12 |
Macrocystic > 1 cm |
1 mg/kg |
Microcystic < 1 cm |
Kumar et al.2626 Kumar V, Kumar P, Pandey A, Gupta DK, Shukla RC, Sharma SP, et al. Intralesional bleomycin in lymphangioma: an effective and safe non-operative modality of treatment. J Cutan Aesthet Surg. 2012;5:133-6.
|
2012 |
India |
prospective study |
35 |
Not available |
1‒2Y |
33 |
Not available |
0.5 mg/kg |
Harjai et al.2727 Harjai MM, Jha M. Intralesional bleomycin and sodium tetradecyl sulphate for haemangiomas and lymphangiomas. Afr J Paediatr Surg. 2012;9:47-51.
|
2012 |
India |
Retrospective study |
30 |
Not available |
0‒20Y |
22 |
Not available |
0.5‒1 mg/kg |
Sandlas et al.2828 Sandlas G, Kothari P, Karkera P, Gupta A. Bleomycin: A worthy alternative. Indian J Plast Surg. 2011;44:50-3.
|
2011 |
India |
Prospective study |
15 |
11/4 |
0‒12Y |
13 |
Not available |
0.6‒0.8 mg/kg |
Niramis et al.2929 Niramis R, Watanatittan S, Rattanasuwan T. Treatment of cystic hygroma by intralesional bleomycin injection: experience in 70 patients. Eur J Pediatr Surg. 2010;20:178-82.
|
2010 |
Thailand |
Retrospective study |
70 |
42/28 |
1M‒14Y |
58 |
Not available |
0.3‒0.6 mg/kg |
Rawat et al.3030 Rawat JD, Sinha SK, Kanojia RP, Wakhlu A, Kureel SN, Tandon RK. Non surgical management of cystic lymphangioma. Indian J Otolaryngol Head Neck Surg. 2006;58:355-7.
|
2006 |
India |
Retrospective study |
19 |
13/6 |
16D‒11Y |
16 |
Not available |
0.1‒0.5 mg/kg |
Mathur et al.3131 Mathur NN, Rana I, Bothra R, Dhawan R, Kathuria G, Pradhan T. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol. 2005;69:75-80.
|
2005 |
India |
Prospective study |
10 |
7/3 |
2M‒10Y |
7 |
Not available |
1‒6 mg/kg |
Sung et al.3232 Sung MW, Chang SO, Choi JH, Kim JY. Bleomycin sclerotherapy in patients with congenital lymphatic malformation in the head and neck. Am J Otolaryngol. 1995;16:236-41.
|
1995 |
Korea |
Retrospective study |
10 |
6/4 |
1Wks‒12Y |
7 |
Not available |
6 mg |
Okada et al.3333 Okada A, Kubota A, Fukuzawa M, Imura K, Kamata S. Injection of bleomycin as a primary therapy of cystic lymphangioma. J Pediatr Surg. 1992;27:440-3.
|
1991 |
Japan |
Retrospective study |
29 |
13/16 |
1M‒12Y |
25 |
Not available |
1‒5 mg/cyst |
Tanigawa et al.3434 Tanigawa N, Shimomatsuya T, Takahashi K, Inomata Y, Tanaka K, Satomura K, et al. Treatment of cystic hygroma and lymphangioma with the use of bleomycin fat emulsion. Cancer. 1987;60:741-9.
|
1987 |
Japan |
Retrospective study |
33 |
Not available |
Not available |
27 |
Not available |
4.45 mg |